Original Research ARTICLE
m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gastric cancer
- 1Department of Thoracic Surgery, Renmin Hospital, Faculty of Medical Sciences, Wuhan University, China
- 2Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
- 3Department of Pathology, Renmin Hospital, Faculty of Medical Sciences, Wuhan University, China
m6A is the most common form of mRNA modification, and is dynamically regulated by the m6A RNA methylation regulators. However, little is known about m6A in gastric cancer. The aim of this work is to investigate the effects of m6A RNA methylation regulators in gastric cancer. Here, we found that most of the thirteen main m6A RNA methylation regulators are higher expressed in 375 patients with gastric cancer. We identified two subgroups of gastric cancer (cluster1 and 2) by applying consensus clustering to m6A RNA methylation regulators. Compared with the cluster1 subgroup, the cluster2 subgroup correlates with a poorer prognosis, and most of the thirteen main m6A RNA methylation regulators are higher expressed in cluster2. Moreover, the cancer-specific pathways are also significantly enriched in the cluster2 subgroup. This finding indicates that m6A RNA methylation regulators are closely associated with gastric cancer. Based on this finding, we derived a risk signature, using 3 m6A RNA methylation regulators(FTO, RBM15, ALKBH5), that is not only an independent prognostic marker but can also predict the clinicopathological features of gastric cancer. Moreover, FTO is higher expressed in high risk scores subtype in gastric cancer. Thus, this first finding provide us clues to understand epigenetic modification of RNA in gastric cancer.
Keywords: gastric cancer, M6A, TCGA, epigenetic modification, FTO
Received: 17 Jul 2019;
Accepted: 24 Sep 2019.
Copyright: © 2019 Su, Wei and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Jichang Hu, Department of Pathology, Renmin Hospital, Faculty of Medical Sciences, Wuhan University, Wuhan, China, email@example.com